Addressing resource allocation issues in recommendations from clinical practice guideline panels: Suggestions from an American College of Chest Physicians task force

Chest

Volumn 129, Issue 1, 2006, Pages 182-187

  Guyatt, Gordon ^a   Baumann, Michael ^b   Pauker, Stephen ^c   Halperin, Jonathan ^d   Maurer, Janet ^l   Owens, Douglas K ^e   Tosteson, Anna N A ^f   Carlin, Brian ^g   Gutterman, David ^h   Prins, Martin ^j   Lewis, Sandra Zelman ⁱ   Schünemann, Holger ^k  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ American College of Chest Physicians   (United States)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^l NONE

more..

Author keywords

Clinical practice guidelines; Evidence based recommendations; Resource allocation

Indexed keywords

ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RESOURCE ALLOCATION; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EID: 33144468773     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.1.182     Document Type: Article

References (14)

1. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283:2116-2121
2. Owens D. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13:716-717
3. Garber A, Phelps C. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16:1-31
4. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481
5. Cost-effectiveness in health and medicine. Oxford, UK: Oxford University Press, 1996
6. Avorn J. Navigating the third dimension: powerful medicines. New York, NY: Alfred A. Knopf, 2004; 235-266
7. Eisenberg J. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989; 262:2879-2886
8. O'Brien B, Drummond M, Richardson W, et al. Economic analysis. In: Guyatt GR, Remie D, eds. Users' guides to the medical literature. Chicago, IL: AMA Press, 2002
9. Luce B, Manning W, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al, eds. Cost-effectiveness in health and medicine. Oxford, UK: Oxford University Press, 1996; 176-213
10. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines. Chest 2006; 129:174-181
11. Torrance G. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5:1-30
12. Schünemann H, Armstrong D, Degl'innocenti A, et al. A randomized multicenter trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Med Care 2004; 42:1132-1142
13. Devereaux P, Anderson D, Gardner M, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323:1218-1222
14. Feeny D, Furlong W, Torrance G, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002; 40:113-128